司美格鲁肽再添力证！这个隐藏功效你了解吗？

Core Viewpoint - The article emphasizes the significant therapeutic potential of Semaglutide for patients with type 2 diabetes and peripheral artery disease (PAD), highlighting its multifaceted benefits beyond glucose control and weight loss [3][10]. Research Objectives - The study aims to analyze whether the efficacy of Semaglutide is consistent across different clinical characteristics in patients with type 2 diabetes and PAD, focusing on key variables such as diabetes duration, body mass index (BMI), HbA1c levels, and concurrent medication use [5][8]. Research Methodology - The STRIDE trial included 792 patients with symptomatic PAD and type 2 diabetes, employing a randomized, double-blind design over 52 weeks to assess the effects of Semaglutide compared to a placebo [7]. Key Assessment Indicators - The primary endpoint was the improvement in maximum walking distance (MWD) after 52 weeks, with supplementary assessments of pain-free walking distance (PFWD) [9]. Research Results - Semaglutide significantly improved both MWD and PFWD across various patient subgroups, indicating a stable therapeutic effect regardless of patient characteristics [10][12]. - The average weight loss was 4.09 kg, and HbA1c levels decreased by 0.99%, but the benefits for PAD appeared to operate through independent mechanisms [11][12]. Safety Profile - The safety profile of Semaglutide was found to be comparable to that of the placebo, with no new safety concerns identified, and common gastrointestinal reactions and hypoglycemia were evenly distributed among subgroups [13]. Conclusion - Semaglutide is positioned as a breakthrough treatment option for patients with type 2 diabetes and PAD, demonstrating efficacy that extends beyond traditional mechanisms, including improvements in endothelial function and anti-inflammatory effects [16].